A comprehensive genomic analysis of neuroendocrine carcinoma of gynecologic and breast tumors

Objective: Neuroendocrine carcinomas (NEC) of gynecologic and breast origin are aggressive histologic subtypes that confer a worse prognosis. We hypothesized that a single comprehensive genomic profiling (CGP) assay could better match breast and gynecologic NEC subsets to mechanistically driven treatment modalities by simultaneously assessing tumor microsatellite instability (MSI), tumor mutation burden (TMB), and targetable genomic alterations (GA).